Patients with multiple sclerosis (MS) are at greater risk of pain than people without the disease; however, the occurrence and characteristics of pain among these patients are incompletely described. We aimed to assess characteristics of pain amongst MS patients using MS patients who were recruited to participate in 3 studies in Sweden (n 5 3877) and were matched with individuals without MS (n 5 4548) by sex, year of birth, and region of residence. The Prescribed Drugs Register identified prescribed pain medication, overall and restricted to those given 4 or more prescriptions in 1 year to assess chronic pain. Anatomical therapeutic chemical codes classified whether pain was neuropathic, musculoskeletal, or migraine. Cox-proportional hazard models were used to estimate associations. Our findings showed patients with MS were at increased risk of pain treatment, with a hazard ratio (HR) of 2.52 (95% confidence interval 2.38-2.66). The largest magnitude HR was for neuropathic pain (5.73, 5.07-6.47) for which 34.2% (n 5 1326) of the MS and 7.15% (n 5 325) of the non-MS cohort were prescribed a treatment. The HR for chronic pain treatment was 3.55 (3.27-3.84), indicating an increased effect size relative to any pain treatment. Chronic neuropathic pain showed the largest HR at 7.43 (6.21-8.89). Neuropathic pain was shown to be the primary mechanism leading to increased risk of pain in patients with MS.
Introduction
Multiple sclerosis (MS) is an autoimmune disease that leads to demyelination and subsequent damage to axons and neurons. 9, 11, 26 Patients with MS are known to be more likely to report experiencing pain than individuals without MS. 6, 27, 33 There are several mechanisms that can cause pain, which are more likely to occur in patients with MS because of their disease. Migraines in particular are believed to affect patients with MS to a greater extent than the general population, and it is believed migraines often occur together with neuropathic pain. 15 The mechanism behind why patients with MS experience migraines is believed to relate to increased nociceptive signalling, or potential early lesions in the central nervous system, because migraines tend to be seen early on in the disease course. 4, 15 Musculoskeletal pain has previously been considered to be a consequence of musculoskeletal dysfunction in MS, 30 including nociceptive pain. Neuropathic pain often derives from damage to the nervous system through lesions or dysfunction, both of which are often present in patients with MS. 32 Diagnosing pain as neuropathic still presents difficulties. 5, 29 The patterns of occurrence and characteristics of pain among patients with MS are incompletely described because of the difficulties in objective measurement. 33 This has resulted in widely varying estimates of the extent to which patients with MS are believed to be affected by pain, with findings ranging from 29% 3 to 86%. 17, 28 The use of medication as a proxy for a diagnosis has commonly been used, eg, to identify depression. 21 Using such an approach can provide a reliable measure with substantial specificity for outcomes such as pain. Swedish register data, which provide information on prescribed drugs, allow us to examine patterns of pain medication utilisation. Pain and prescription of pain medication in patients with MS will not only be due to MS itself, but by comparing with a general population cohort, it is possible to identify an excess of pain medication use among this patient group, with the possibility to identify some more specific subtypes of pain. Identification of pain in this way will allow insight into the extent that patients with MS receive treatment for some phenotypes of pain compared with people without MS. Such a quantification of treated pain among patients with MS compared with the general population has not, as far as we are aware, been previously published and will provide quantified evidence for this suspected association.
Methods

Data
Data collected in the context of the Epidemiological Investigation of Multiple Sclerosis (EIMS), 22 Genes and Environment in Multiple
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Sclerosis (GEMS), 23 and Immunomodulation of Multiple Sclerosis Epidemiology (IMSE) 24 studies were used. A sample of patients with MS (n 5 3877) was matched with up to 2 individuals without MS (n 5 4548) by sex, year of birth, and place of residence in Sweden using the Total Population Register. Date of study entry was defined as either the date of MS diagnosis for the patient with MS within the risk set, or July 1, 2005, whichever occurred last. Information from the Swedish Prescribed Drugs Register (PDR), which began in July 2005, was used to identify when pain medication had been prescribed. The register does not include over the counter purchases, and only medication which was prescribed was used in this study. The longitudinal integration database for health insurance and labour market studies (LISA) provided information on highest educational attainment. Information on date of death was obtained from the Causes of Death register.
Outcome
Any prescription of pain medication recorded in the PDR after entry was defined as an event. For all pain, an outcome occurred if any anatomical therapeutic chemical code for pain relief was identified (Appendix A, available online at http://links.lww.com/ PAIN/A685). A second analysis looking at chronic pain was conducted, where individuals who were prescribed pain medication at least 4 times in 1 year were defined as having chronic pain. This definition was selected because prescriptions in Sweden usually provide treatment for 3 months at a time. All patients in our study had at least 1 year of follow-up available, so no exclusions were made because of the lack of follow-up for this definition. A sensitivity analysis that used the definition of continuous pain medication use for 6 months with less than a 31-day gap was also undertaken to ensure that the risk estimates remained stable when alternative definitions of the outcome were applied.
We used prescriptions for pregabalin, gabapentin, amitriptyline, capsaicin, and nortriptyline to identify instances of neuropathic pain. Pregabalin and gabapentin are commonly used in the treatment of epilepsy, so a sensitivity analysis was performed excluding anyone identified as having an epilepsy diagnosis using the patient register (n 5 166). Amitriptyline and nortriptyline are often used in the treatment of depression, so those given a diagnosis of depression in the patient register (n 5 575) were excluded for the purposes of a second sensitivity analysis. Both epilepsy and depression are more common amongst patients with MS, 12,13 so these analyses are important additions to the main analysis. Given that it is possible the treatments were prescribed for dual use of epilepsy/depression and pain, we decided to keep these patients in the main analysis and use the sensitivity analyses to assess whether these patients influence conclusions. For migraine, only prescriptions of antimigraine preparations were included in the outcome. Musculoskeletal pain was identified primarily through muscle relaxants (Appendix Table  A , available at http://links.lww.com/PAIN/A685). Medications were chosen to assist with identifying pain phenotypes relevant to MS, as well as other more general pain treatments, to gain an overall view of how pain affects this patient group.
Pain medication prescriptions before study entry were disregarded.
Statistical analysis
Cox-proportional hazard models were used, with time spent in the study as the underlying time scale. Multivariable analysis included MS exposure with adjustment for the matching factors and highest educational attainment (divided into compulsory education or less, upper secondary, further/higher education, or missing educational information) as covariates. For patients who were diagnosed with MS before July 1, 2005, this date was used as start of follow-up. For patients who entered the study at a later date, date of MS diagnosis was used as start of follow-up. Followup ended at death, date of pain medication prescription, or at the end of the study on December 31, 2014, whichever occurred first. For analysis of chronic pain, the date of fourth pain medication prescription within a year indicated the end of follow-up to reduce the impact of immortal time bias. Defining chronic pain through multiple prescriptions increases the risk of immortal time bias because only those remaining alive and living in Sweden are able to continue collecting prescriptions. We have therefore restricted the analysis of chronic pain to individuals with at least 1 year of follow-up after their first relevant prescription. Chronic pain was defined where a total of 4 or more prescriptions were collected by the end of that year.
An analysis of whether age affected the likelihood of pain was considered using a sensitivity analysis for which only patients with MS were included in the model, and the oldest age group (501 years) was used as the reference category. Only diagnoses on or after 2005 were included for this analysis, and duration since MS diagnosis was used as the underlying time scale.
Waiting time distributions, which indicate the proportion of a given cohort prescribed a treatment at any given point in time, were used as graphical representations of whether most users were likely prevalent or incident. A high left-skewed peak represents a larger proportion of prevalent users, whereas roughly equal bars throughout time indicate a large proportion of incident users.
The proportional hazard assumption was tested by interacting exposure with the time scale; a stratification for year of entry was included in the model if these assumptions were violated. SAS version 9 and STATA version 13 were used for analysis.
Ethics approval from the regional ethics committee for Stockholm was granted for this study.
Results
Among those treated, the median time spent in the study before being prescribed pain medication was 0.7 (interquartile range 0.2-2.4) years for patients with MS and 2.8 (interquartile range 1.0-5.4) years among the non-MS cohort ( Table 1) . For patients with MS, 79.5% (n 5 3082) were prescribed medication after study entry, whereas 59.2% (n 5 2285) of the non-MS cohort were prescribed pain medication after study entry. Some 34.2% (n 5 1326) of the MS and 7.15% (n 5 325) of the non-MS cohort were prescribed treatment for neuropathic pain. Regarding treatment for musculoskeletal pain, 6.1% (n 5 235) of the MS cohort and 6.6% (n 5 299) of the non-MS cohort were prescribed these treatments during the study period. For antimigraine preparations, 6.5% (n 5 250) of the MS cohort and 5.4% (n 5 247) of the non-MS cohort received prescriptions during the study period.
Overall, when the MS and non-MS cohorts were compared, this produced an adjusted hazard ratio (HR) of 2.52 (95% confidence interval 2.38-2.66, P , 0.001) for pain medication ( Table 2) . These results remained relatively stable across strata with little difference in the magnitude of the effect between men and women. The waiting time distributions showed a high proportion of patients with MS were likely to be prevalent users due to the left-skewed peak, whereas the flat bars for non-MS patients indicated that a high proportion of non-MS individuals were likely to be incident users (Fig. 1) . The magnitude of the difference between the cohorts was larger for those with higher educational attainment, and for those in the younger age groups at diagnosis. The HR rose to 3.55 (3.27-3.84, P , 0.001) when estimating the risk for chronic use of pain medication. Patients with MS were found to be at particularly elevated risk of neuropathic pain relative to their non-MS comparators, with a HR of 5.73 (5.07-6.47, P , 0.001) for any use, and 7.43 (6.21-8.89 P , 0.001) for chronic use of treatment for neuropathic pain. The HR for musculoskeletal pain treatment was 0.90 (0.76-1.06, P 5 0.22) for any use, and 1.33 (0.83-2.14, P 5 0.24) for chronic users. Patients with MS had an HR of 1.20 (1.01-1.43, P 5 0.04) for use of antimigraine preparation relative to their non-MS comparators, which rose to an HR of 1.44 (1.14-1.83, P 5 0.004) when considering chronic use.
Details of the distributions by cohorts using the definition of 4 prescriptions in a year, and for continuous use for 6 months with a ,31-day gap are shown in Table 3 and Appendix Table B (available at http://links.lww.com/PAIN/A685). The sensitivity analysis looking at 6 months of continuous exposure with a ,31-day gap showed the results remained stable when the definition of chronic pain was altered.
The waiting time distributions, defined as the time from study entry until the first event highlighted the more frequent use amongst patients with MS (Figs. 1-4) . The left-skewed distribution was observed for all pain medication categories except musculoskeletal pain for patients with MS. For non-MS cohort members, the distribution is relatively even over time for overall pain, musculoskeletal, and neuropathic pain. The distributions of migraine treatment are fairly similar between the MS and non-MS cohorts.
Sensitivity analyses were performed first excluding epilepsy patients and then excluding patients diagnosed with depression. There were no major alterations to the HRs for either sensitivity analysis.
The results of an analysis, which considered age and pain amongst patients with MS showed those who had been living with MS for the same amount of time were at increased risk of pain if they were younger ( Table 4) .
Discussion
Patients with MS were at an over 5-fold increased risk of receiving treatment for neuropathic pain. This pain type seemed to be the primary factor behind the overall increased risk of pain treatment for patients with MS. Treatment for musculoskeletal pain was not shown to be different between the 2 cohorts; however, this may be at least partially because of other therapies, which often target spasticity resulting in musculoskeletal pain amongst the MS cohort, but not amongst the non-MS group. 19 The increased risk of migraine treatment for patients with MS was approximately 45% and was much more common among women than men for both cohorts. The magnitude of the difference between the cohorts was even higher for chronic use of migraine medication. The difference for the pooled pain medication analysis showed patients with MS to be at an over 2-fold increased risk of being prescribed any painkiller.
It has been suggested that potential factors behind the increased risk of neuropathic pain include pain induced by somatosensory system lesions 34 and peripheral nerve injury due to inflammation. 10 Spinal lesions have also been proposed as a possible mechanism, particularly in pain which is felt symmetrically in both feet and legs, with some patients also experiencing pain in the hands. In some patients, this pain is experienced if exposed to cold temperatures or when pressure is applied, which also supports the concept of neuropathic pain being triggered through a spinal lesion. 18 The sensitivity analysis which excluded patients with epilepsy showed minimal differences to the overall analysis because of the small number diagnosed with epilepsy, suggesting most patients were prescribed these treatments for pain. There were also no major differences to the results when patients diagnosed with depression were excluded (n 5 575). Patients with MS were at marginally increased risk of migraine, although the magnitude was much less than for neuropathic pain. 15 The elevated risk of migraine has previously been suggested to relate to brainstem lesions and inflammatory processes, 7 although such links have not been conclusively verified. Another proposed mechanism is headache induced by MS treatment. 7 The importance of screening MS patients with migraine symptoms is therefore a potentially vital step in the diagnostic process due to the implications this can have for treatment. 31 When considering the analysis defining those with an outcome as 4 or more prescriptions during 1 year, the magnitude of the increased risk was higher for patients with MS relative to the definition used for any pain. This suggests patients with MS are at increased risk of chronic pain to a greater degree than being diagnosed with sporadic pain. Patients being prescribed pain medication most likely for musculoskeletal pain were much less likely to be prescribed multiple treatments during a year. For neuropathic pain, the definition of 4 prescriptions within a year did not substantially reduce the number of individuals with an outcome, suggesting neuropathic pain tends to be chronic and treated over a long period, in contrast with musculoskeletal pain. It was also evident that the relative risk of neuropathic pain treatment for patients with MS was higher when considering chronic neuropathic pain treatment. Migraine treatment showed a similar pattern to neuropathic pain, with those with prescriptions for migraine more likely to be chronic users of antimigraine preparations. Waiting time distributions, which are a tool used to assess whether a treatment has a large number of prevalent rather than incident users, 25 provided insight into the frequency with which the MS and non-MS cohorts were being prescribed pain medication overall and for each pain treatment type (Figs. 1-4) . These distributions plot the first time a treatment was prescribed to assess what proportion of the study population received the treatment after study entry. A high and narrow left-skewed peak would indicate that most users are prevalent. The distributions had a clear left-skew overall and for all pain types for patients with MS aside from musculoskeletal pain, highlighting a relatively short time between prescriptions, which indicates a large proportion of prescriptions are for prevalent users. This would be expected from a group being treated for chronic pain. The distributions for the non-MS cohort are much more even over the study period, suggesting pain medications are being prescribed sporadically over the study period rather than being used for chronic pain through repeat prescriptions. The only exception to this is for the non-MS cohort for antimigraine preparations, for which the left skew was apparent to a similar degree for both the MS and non-MS cohorts. This may be because migraine is a chronic disease, 8 and therefore, prescription patterns for migraine will likely replicate those usually seen for other chronic treatments. For musculoskeletal pain, the left skew is not evident in either of the cohorts, perhaps because patients with MS are often prescribed baclofen and other treatments targeting spasticity, which relieves both the spasticity symptoms, and the musculoskeletal pain that accompanies them. 14 For members of the non-MS cohort, the use of musculoskeletal pain medication may be prescribed, eg, after an injury. When treatments are prescribed for an injury, a left skew would not be expected unless the injury leads to chronic pain.
The analysis looking at the impact of age on pain treatment for patients with MS showed younger patients were more likely to receive pain medication than older patients who had been living with the disease for the same amount of time ( Table 4) . The reasons for this are unclear but may relate to different disease characteristics in patients with younger MS onset.
A major strength of this study was the large sample size and long follow-up time, allowing for the clarification of associations between MS and pain medication. The use of prescription register data allowed for an objective approach rather than the study being wholly reliant on questionnaires, which has been the case for most of the previous studies into MS and pain. The inclusion criteria were robust and included initial identification of MS during patient clinic visits, which reduced the likelihood of people without MS being included in the MS cohort.
Some potential limitations to the study should be considered. First, only individuals who agreed to participate in the study, which included the completion of a questionnaire and subsequent tests, such as the collection of genetic information, were included in the study population. Individuals who participate in surveys are believed to differ in certain characteristics to those who decline, which could potentially induce bias and problems with generalisability to the results.
1,2 However, it is not clear whether it would be differential by MS. Second, we relied on anatomical therapeutic chemical codes associated with pain relief as a proxy for pain, which means any individuals who were prescribed these drugs for another purpose will have been classified as having an outcome of pain or a certain pain type in this study. The main exception to this is patients with epilepsy because these patients are commonly prescribed pregabalin and gabapentin and were therefore removed for the purposes of a sensitivity analysis with the intention that most of the remaining subjects will have been prescribed these drugs for pain management. The same sensitivity analysis was performed excluding patients with a diagnosis of depression, for which amitriptyline and nortriptyline can be prescribed. The opposite may also apply in some cases, ie, individuals with pain or a specific pain type may not have been identified because of the particular criteria we applied for identifying these outcomes. This means patients which use, eg, ibuprofen or naproxen for migraines will not have been included in the migraine analysis. For musculoskeletal pain, baclofen is often used in the treatment of spasticity, with the additional intention of treating the nociceptive pain that can accompany it. 20 The decision to exclude treatments used for spasticity resulted in a probable underestimate of musculoskeletal pain treatment for patients with Table 3 Hazard ratios (HRs) and 95% CIs for having 4 or more pain prescriptions within a year among cohorts with and without MS. 16 Surveillance bias is likely playing a role in the increased risk of being prescribed pain medication because patients with MS receive free prescriptions, which is not the case for members of the non-MS cohort, unless they have another chronic illness, which makes them eligible for free prescriptions. This could result in increased likelihood that those without MS more often buy over the counter treatments that do not appear in the PDR, rather than receiving prescriptions. However, most drugs used in this study must be prescribed by a physician. A limitation particular to the analysis of chronic pain is the difficulty in measuring ongoing, long-term pain treatment while accounting for the fact that for the treatment to be The increased risk of pain treatment was particularly elevated for neuropathic pain, indicating this may be the primary explanation for a greater occurrence of pain and pain treatment in patients with MS. Patients with MS were shown to be more likely than non-MS participants to use repeat prescriptions for pain indicating a greater likelihood of chronic pain, particularly chronic neuropathic pain. Further studies are needed to address whether early intervention with effective MS disease modulatory treatments affect the risk of developing chronic neuropathic pain conditions in later disease stages. 
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